Insider Buying News: Merrimack Pharmaceuticals Inc (MACK), Opko Health Inc. (OPK), NewLink Genetics Corp (NLNK), GTx, Inc. (GTXI)


Recently, various healthcare executives have taken part in insider buying activity for the stocks of Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Opko Health Inc. (NYSE:OPK), NewLink Genetics Corp (NASDAQ:NLNK), and GTx Inc (NASDAQ:GTXI)

Merrimack Pharmaceuticals Inc

Director Michael Porter bought $8,284 shares worth $$97,668 at an average price of $11.79, as reported in the SEC filing on May 15. Following the insider-buying transaction, his stake in Merrimack Pharmaceuticals has now grown to $661,448.00 shares with a value of $8,221,799.

Opko Health Inc.

Opko Health has been backed by positive insider activity as the company’s CEO & Chairman, Phillip Frost, acquired a total of $6,000 shares in multiple transactions dated May 13, taking his total stake to $176,876,336 shares. The stock purchase was worth $93,315 at an average price of $15.55 per share.

NewLink Genetics Corp

Chief Financial Officer and Executive Vice President John Henneman yesterday purchased $3,000 shares, valued at $111,900. After completion of the transaction, Henneman owns 50,489 NewLink shares, worth $1,952,410.

GTx, Inc.

The Executive Chairman of GTx, Wills Robert James, acquired 46,140 shares (worth $44,247) at a price of $0.96 in two transactions dated May 13 and May 14. The executive now has a total stake of 100,000 GTx shares worth $100,000.

According to TipRanks.com, which measures corporate insiders’ success based on their transactions, Wills Robert James has an average return of 7.9% and a 66.7% success rate. James is ranked #12459 out of 35774 corporate insiders.